DDInter575 DDInter1376
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Disopyramide {u} (Compound) resembles {v} (Compound) Dextropropoxyphene
Disopyramide {u} (Compound) resembles {v} (Compound) Isopropamide
Disopyramide {u} (Compound) binds {v} (Gene) CHRM2
Disopyramide {u} (Compound) upregulates {v} (Gene) KIAA0355
Disopyramide {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Disopyramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylprednisolone
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Abarelix
Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Disopyramide (Compound) resembles Isopropamide (Compound)
Disopyramide (Compound) binds CHRM2 (Gene)
Disopyramide (Compound) upregulates KIAA0355 (Gene)
Disopyramide (Compound) causes Cardiac arrest (Side Effect)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human
Disopyramide may lead to a major life threatening interaction when taken with Entrectinib
Disopyramide may lead to a major life threatening interaction when taken with Abarelix